CAMBRIDGE, Mass., May 16, 2017 /PRNewswire/ -- TCR2 Therapeutics Inc. announced today that its Chief ExecutiveOfficer, Garry E. Menzel, Ph.D., will present a corporate overview at the UBS Global Healthcare Conference on Tuesday, May 23, 2017 at 9:30 AM Eastern Time. The
About TCR2 Therapeutics TCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). TCR2 has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believes its TRuC™-reprogrammed T cells will serve as a backbone for solid tumor therapies. TCR2 was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tcr2-therapeutics-to-present-at-the-2017-ubs-global-healthcare-conference-300457998.html
SOURCE TCR2 Therapeutics
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All